Troponins in Heart Failure - a Perpetual Challenge

Area of Science:

• Cardiology
• Biomarker Research
• Clinical Diagnostics

Background:

• Increased cardiac troponin (cTn) levels are common in heart failure (HF), correlating with pathogenesis, diagnosis, and prognosis.
• High-sensitivity troponin assays (hs-cTn) improve detection but complicate interpretation compared to conventional troponin testing.
• Elevated cTn in HF can signify acute myocardial infarction (AMI) if other diagnostic criteria are met.

Discussion:

• Sub-AMI threshold elevations in cTn suggest acute or chronic myocardial injury, identifiable through serial testing trends.
• In both acute and chronic HF, elevated cTn levels are significant prognostic indicators for adverse cardiovascular events.
• Differential diagnosis is crucial, as various conditions like hypertensive crises, arrhythmias, myocarditis, and stroke can transiently increase cTn levels, mimicking acute coronary syndrome (ACS).

Key Insights:

• Multiple mechanisms contribute to elevated cTn, including myocardial necrosis, coronary thrombosis, ischemia-reperfusion injury, inflammation, and neurohormonal activation.
• hs-cTn screening in high-risk populations provides prognostic information regarding new-onset HF and other cardiovascular events.
• Understanding cTn kinetics and clinical context is vital for accurate diagnosis and risk stratification in HF patients.

Outlook:

• Further research into the precise mechanisms of cTn elevation in non-AMI HF is warranted.
• Standardized interpretation guidelines for hs-cTn in HF are needed to improve clinical decision-making.
• Integrating cTn data with other clinical and imaging findings will enhance personalized risk assessment and management strategies.